
样式: 排序: IF: - GO 导出 标记为已读
-
Tobacco, Alcohol, Heroin, Binge Eating, and Behavioral Addictions. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01 Ned H Kalin
-
Prospective Associations Between Tobacco Product Use and Mental Health and Substance Use Problems Among U.S. Adolescents and Adults. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01 Kevin P Conway,Emmanuella Michel,Sam Eig,Jian-Ping He,Kathleen R Merikangas
OBJECTIVE The authors examined prospective associations between tobacco product use and mental health and substance use problems among U.S. adolescents and adults. METHODS Covariate-adjusted models using discrete-time survival analysis of five annual waves (2013-2014 to 2018-2019) were used to examine the links between specific tobacco product use and mental health and substance use problems among
-
Tobacco Use Is Associated With Mental Illness and Substance Use Problems-Now What? Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01 Judith J Prochaska
-
Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01 Andrea C King,Andrew M Fischer,John F Cursio,Nathan A Didier,Zoe Lee,Daniel J Fridberg
OBJECTIVE The allostasis theory states that, as addiction develops, alcohol is consumed to relieve negative affect rather than to produce positive effects. This study aimed to investigate the real-time subjective effects of alcohol in individuals with alcohol use disorder (AUD) and those prone to negative affect by virtue of having comorbid depressive disorder (DEP). METHODS Participants (N=221) completed
-
Understanding the Effects of Combined Lisdexamfetamine and Cognitive Behavior Therapy for Adults With Binge Eating Disorder. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01 Tom Hildebrandt,Elizabeth Martin
-
Using Genetically Diverse Rats to Identify Individual Differences in Addiction-Related Behaviors and Brain Activity. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01 Ginevra D'Ottavio,Kenichiro Negishi,Yavin Shaham
-
Varenicline as a First-Line Treatment for Individuals With Current Major Depressive Disorder Who Smoke Cigarettes. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01 Andrea H Weinberger,Marc L Steinberg
-
Correcting Overestimations in Self-Harm Visit Data. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01 Abid Rizvi
-
Correcting Overestimations in Self-Harm Visit Data: Response From Bommersbach and Colleagues. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01 Tanner J Bommersbach,Mark Olfson,Taeho Greg Rhee
-
A Fresh Look at the Allostasis Theory of Addiction. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-02-01 Markus Heilig
-
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-29 Konstantinos N Fountoulakis,Athanasios Saitis,Alan F Schatzberg
OBJECTIVE Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. The authors conducted a systematic review and meta-analysis of the available data on its efficacy against depression and suicidality as well as its side effects. METHODS MEDLINE was searched with the keyword "esketamine" on March 24
-
Spaced Transcranial Direct Current Stimulation for Major Depression. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-29 Maxime Couture,Véronique Desbeaumes Jodoin,Emma Bousseau,Arash Sarshoghi,Michael A Nitsche,Daniel M Blumberger,Chantal Bolduc,Cory R Weissman,Lawrence G Appelbaum,Zafiris J Daskalakis,Mohsen Poorganji,Paul Lespérance,Jean-Philippe Miron
OBJECTIVE This study investigated spaced transcranial direct current stimulation for major depressive disorder, focusing on feasibility. METHODS In a prospective open-label study, 30 participants with major depressive disorder were enrolled to receive a 50-session transcranial direct current stimulation (tDCS) treatment over 2 weeks. The feasibility, safety, tolerability, and preliminary therapeutic
-
Randomized Controlled Trial of the Effects of High-Dose Ondansetron on Clinical Symptoms and Brain Connectivity in Obsessive-Compulsive and Tic Disorders. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-29 Emily R Stern,Katherine A Collins,Laura B Bragdon,Goi Khia Eng,Nicolette Recchia,Barbara J Coffey,Evan Leibu,James W Murrough,Russell H Tobe,Dan V Iosifescu,Katherine E Burdick,Wayne K Goodman
OBJECTIVE Sensory phenomena (SP) are aversive sensations driving repetitive behaviors in obsessive-compulsive disorder (OCD) and Tourette's disorder that are not well addressed by standard treatments. SP are related to the functioning of an interoceptive-sensorimotor circuit that may be modulated by the 5-HT3 receptor antagonist ondansetron. The present study employed an experimental medicine approach
-
Use of Telemental Health Care by Children and Adolescents in the United States. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-15 Mark Olfson,Chandler McClellan,Samuel H Zuvekas,Melanie Wall,Carlos Blanco
-
Distinct Behavioral Profiles and Neuronal Correlates of Heroin Vulnerability Versus Resiliency in a Multi-Symptomatic Model of Heroin Use Disorder in Rats. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-15 Brittany N Kuhn,Nazzareno Cannella,Ayteria D Crow,Veronica Lunerti,Arkobrato Gupta,Stephen J Walterhouse,Carter Allen,Reda M Chalhoub,Eric Dereschewitz,Analyse T Roberts,Mackenzie Cockerham,Angela Beeson,Rusty W Nall,Abraham A Palmer,Gary Hardiman,Leah C Solberg Woods,Dongjun Chung,Roberto Ciccocioppo,Peter W Kalivas
OBJECTIVE The behavioral and diagnostic heterogeneity within the opioid use disorder (OUD) diagnosis is not readily captured in current animal models, limiting the translational relevance of the mechanistic research that is conducted in experimental animals. The authors hypothesized that a nonlinear clustering of OUD-like behavioral traits would capture population heterogeneity and yield subpopulations
-
Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions? Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-15 Marjorie R Levinstein,Reece C Budinich,Jordi Bonaventura,Alan F Schatzberg,Carlos A Zarate,Michael Michaelides
Ketamine is a racemic compound and medication comprised of (S)-ketamine and (R)-ketamine enantiomers and its metabolites. It has been used for decades as a dissociative anesthetic, analgesic, and recreational drug. More recently, ketamine, its enantiomers, and its metabolites have been used or are being investigated for the treatment of refractory depression, as well as for comorbid disorders such
-
Five-Year Outcomes of a School-Based Personality-Focused Prevention Program on Adolescent Substance Use Disorder: A Cluster Randomized Trial. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-15 Patricia Conrod,Sherry H Stewart,Jean Seguin,Robert Pihl,Benoit Masse,Sean Spinney,Samantha Lynch
OBJECTIVE Rates of substance use disorders (SUDs) remain significantly above national targets for health promotion and disease prevention in Canada and the United States. This study investigated the 5-year SUD outcomes following a selective drug and alcohol prevention program targeting personality risk factors for adolescent substance misuse. METHODS The Co-Venture trial is a cluster randomized trial
-
Psychedelic Regulation Beyond the Controlled Substances Act: A Three-Dimensional Framework for Characterizing Policy Options. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01 Maha N Mian,Michael T Dinh,Allison R Coker,Jennifer M Mitchell,Brian T Anderson
-
Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01 Broc A Pagni,Richard J Zeifman,Sarah E Mennenga,Brennan M Carrithers,Noam Goldway,Snehal Bhatt,Kelley C O'Donnell,Stephen Ross,Michael P Bogenschutz
OBJECTIVE Evidence suggests that psilocybin-assisted therapy (PAT) leads to durable shifts in personality structure. However, such changes have yet to be characterized in disorders of addiction. In this secondary analysis from a randomized controlled trial, the authors examined the effect of PAT on personality dimensions in patients with alcohol use disorder (AUD), hypothesizing that PAT would attenuate
-
Primum Non Nocere: The Onus to Characterize the Potential Harms of Psychedelic Treatment. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01 Sharmin Ghaznavi,Jeremy N Ruskin,Stephen J Haggerty,Franklin King,Jerrold F Rosenbaum
The last few years have seen exponential growth in interest, investment, advocacy, and research into psychedelics as therapeutics. This reflects an optimism about the potential promise of psychedelics as therapeutics. As with all therapeutic interventions, research is needed not only into their benefits but also potential risks. Indeed, when substances with therapeutic potential are scrutinized over
-
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01 Roger S McIntyre,Angela T H Kwan,Rodrigo B Mansur,Albino J Oliveira-Maia,Kayla M Teopiz,Vladimir Maletic,Trisha Suppes,Stephen M Stahl,Joshua D Rosenblat
During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain psychedelics are effective and safe in the treatment of major depressive disorder, treatment-resistant depression, and posttraumatic stress disorder. Preliminary
-
Psychedelics in Psychiatry: Oh, What A Trip! Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01 Gregory A Fonzo,Charles B Nemeroff,Ned Kalin
-
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01 Scott T Aaronson,Andrew van der Vaart,Tammy Miller,Jeffrey LaPratt,Kimberly Swartz,Audrey Shoultz,Margo Lauterbach,Trisha Suppes,Harold A Sackeim
OBJECTIVE Depression varies along a difficulty-to-treat spectrum. Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD). The objective of this study was to document the safety and efficacy of psilocybin in patients with severe TRD. METHODS This was a 12-week, open-label trial conducted at Sheppard Pratt Hospital.
-
Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01 Aaron S Wolfgang,Vetisha L McClair,Paula P Schnurr,Paul E Holtzheimer,Josh D Woolley,Christopher S Stauffer,R Cameron Wolf,Leith J States,David M Benedek,Vincent F Capaldi,John Bradley,Matthew A Fuller,Miriam J Smyth,Eric D A Hermes,Wendy Tenhula,Ilse R Wiechers
-
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01 Johannes G Ramaekers,Johannes T Reckweg,Natasha L Mason
Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an intense but
-
Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01 Namik Kirlić,Molly Lennard-Jones,Merve Atli,Ekaterina Malievskaia,Nadav L Modlin,Stephanie Knatz Peck,Alice Gaillard,Guy M Goodwin,Don Koelpin
The psychedelic experience can be challenging. There is a need for a structured framework for providing psychological support to individuals with mental health conditions receiving investigational psilocybin treatment. The primary benefit of such a framework is to support a safe and meaningful psilocybin experience. It also enables future research on the facets of psychological support and/or psychotherapy
-
Psilocybin: From Psychiatric Pariah to Perceived Panacea. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01 Gregory A Fonzo,Aaron S Wolfgang,Bryan R Barksdale,John H Krystal,Linda L Carpenter,Nina V Kraguljac,Adrienne Grzenda,William M McDonald,Alik S Widge,Carolyn I Rodriguez,Charles B Nemeroff
OBJECTIVE The authors critically examine the evidence base for psilocybin administered with psychological support/therapy (PST) in the treatment of psychiatric disorders and offer practical recommendations to guide future research endeavors. METHODS PubMed was searched for English-language articles from January 1998 to November 2023, using the search term "psilocybin." A total of 1,449 articles were
-
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01 Kelley C O'Donnell,Jim Grigsby,Charles S Grob
-
Toward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-01-01 David E Olson
-
Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-11 Carlos M Grilo,Valentina Ivezaj,Cenk Tek,Sydney Yurkow,Ashley A Wiedemann,Ralitza Gueorguieva
OBJECTIVE Binge-eating disorder (BED) is a prevalent, costly public health problem associated with serious functional impairments and heightened rates of psychiatric and medical comorbidities. Few evidence-based treatments are currently available for BED. We tested the effectiveness of cognitive-behavioral therapy (CBT), lisdexamfetamine (LDX), and combined CBT+LDX, for BED comorbid with obesity. METHODS
-
Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-11 George Kypriotakis,Paul M Cinciripini,Charles E Green,David Lawrence,Robert M Anthenelli,Jennifer A Minnix,Diane Beneventi,Chad Morris,Maher Karam-Hage,Janice A Blalock
OBJECTIVE The aim of this study was to compare the safety and efficacy of the leading smoking cessation medications among individuals with current versus past major depressive disorder (MDD). METHODS This was a secondary analysis of a randomized, double-blind trial over 12 weeks with varenicline or bupropion, followed by a 12-week assessment, in participants ages 18-75 with past (N=2,174) or current
-
Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-11 Matthias Brand,Stephanie Antons,Beata Bőthe,Zsolt Demetrovics,Naomi A Fineberg,Susana Jimenez-Murcia,Daniel L King,Gemma Mestre-Bach,Tania Moretta,Astrid Müller,Elisa Wegmann,Marc N Potenza
Gambling disorder is the only behavioral addiction recognized as a clinical disorder in DSM-5, and Internet gaming disorder is included as a condition requiring further research. ICD-11 categorizes gambling and gaming disorders as disorders due to addictive behaviors. Additional behavioral addictions may include compulsive sexual behavior disorder, compulsive buying-shopping disorder, and problematic
-
The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-11 William P Horan,Colin Sauder,Philip D Harvey,Ian S Ramsay,Samantha E Yohn,Richard S E Keefe,Vicki G Davis,Steven M Paul,Stephen K Brannan
OBJECTIVE Xanomeline and trospium chloride (formerly known as KarXT), a novel M1/M4 muscarinic receptor agonist, demonstrated efficacy across phase 2 and 3 trials as monotherapy for the treatment of inpatients with acute schizophrenia on the Positive and Negative Syndrome Scale total score primary endpoint. In the phase 2 trial, xanomeline/trospium improved performance on a cognitive outcome measure
-
The Importance and Limitations of Null Findings. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-01 Dan J Stein,Jack van Honk,Paul M Thompson
-
Pathways to Homelessness: Childhood Maltreatment and Psychiatric Symptoms Increase Risk of Homelessness. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-01 Cathy Spatz Widom,Kellie Courtney,Hang Heather Do
OBJECTIVE Homelessness is a serious and increasing public health concern. Childhood maltreatment and psychiatric problems have been associated with homelessness as risk factors; however, reliance on cross-sectional studies introduces ambiguity into interpreting previous findings. This study seeks to understand whether psychiatric symptoms in part explain the relationship between childhood maltreatment
-
Centering Agency and Choice in Moving Toward Social Justice in Mental Health: Reflections on Childhood Maltreatment, Psychiatric Symptoms, and Homelessness. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-01 Ana Carolina Florence,Ezra Susser
-
An Honest Reckoning With the Amygdala and Mental Illness. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-01 Andrew S Fox,Alexander J Shackman
Anxiety disorders are a leading source of human misery, morbidity, and premature mortality. Existing treatments are far from curative for many, underscoring the need to clarify the underlying neural mechanisms. Although many brain regions contribute, the amygdala has received the most intense scientific attention. Over the past several decades, this scrutiny has yielded a detailed understanding of
-
Charting the Neural Pathways From Discrimination to Mental Health Disparities. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-01 Erika E Forbes
-
Novel Pharmacologic and Other Somatic Treatment Approaches for Posttraumatic Stress Disorder in Adults: State of the Evidence. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-01 Lauren M Sippel,Jessica L Hamblen,Benjamin Kelmendi,Jonathan E Alpert,Linda L Carpenter,Adrienne Grzenda,Nina Kraguljac,William M McDonald,Carolyn I Rodriguez,Alik S Widge,Charles B Nemeroff,Paula P Schnurr,Paul E Holtzheimer,
Posttraumatic stress disorder (PTSD) is a highly prevalent psychiatric disorder that can become chronic and debilitating when left untreated. The most commonly recommended first-line treatments for PTSD among adults are individual trauma-focused psychotherapies. Other evidence-based treatments include specific antidepressant medications and non-trauma-focused psychotherapies. Despite the effectiveness
-
Homelessness, Discrimination, PTSD, Autism, and the Amygdala. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-01 Ned H Kalin
-
With Apologies to Monty Python: Is Every Cell Sacred? Am. J. Psychiatry (IF 15.1) Pub Date : 2024-12-01 Michaela E Price,Zoé A McElligott
-
Older Adults are at Heightened Risk of the Effects of Cannabis Use. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-11-01 Art Walaszek
-
Addressing Disparities in Alcohol Use Disorder Treatment: A Call to Action. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-11-01 Henry R Kranzler,Rachel Vickers-Smith
-
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-11-01 Lewei Allison Lin
-
Disparities in Treatment for Alcohol Use Disorder Among All of Us Participants. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-11-01 Phuc Le,Jacob James Rich,Eden Y Bernstein,Joseph Glass,Hamlet Gasoyan,Sudie E Back,Thanh C Bui,Gina Ayers,Michael B Rothberg
OBJECTIVE The authors examined racial/ethnic and socioeconomic disparities in receiving treatment for alcohol use disorder (AUD). METHODS A retrospective cohort study was conducted that included adults (≥18 years) with AUD from the All of Us Controlled Tier database v7. Outcomes were lifetime receipt of FDA-approved medications (disulfiram, acamprosate, and naltrexone), psychotherapy (individual, family
-
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-11-01 Wilson M Compton,Emily B Einstein,Beth Han
-
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Borderline Personality Disorder. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-11-01 George A Keepers,Laura J Fochtmann,Joan M Anzia,Sheldon Benjamin,Jeffrey M Lyness,Ramin Mojtabai,Mark Servis,Lois Choi-Kain,Kaz J Nelson,John M Oldham,Carla Sharp,Amanda Degenhardt,Laura J Fochtmann,John M Oldham,Seung-Hee Hong,Jennifer Medicus
-
Higher Prevalence Estimates of Substance Use Disorders With DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use: The Role of DSM-IV Diagnostic Orphans. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-11-01 Deborah Hasin,Malka Stohl
-
Reductions in Substance Use as Outcome Targets for Treatment Development. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-11-01 Wilson M Compton,Nora D Volkow
-
What Are the Genetic Building Blocks of Alcohol-Related Behaviors? Am. J. Psychiatry (IF 15.1) Pub Date : 2024-11-01 Joel Gelernter,Joseph D Deak
-
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use? Am. J. Psychiatry (IF 15.1) Pub Date : 2024-11-01 Finnegan J Calabro,Ashley C Parr
-
Translational Insights From Cell Type Variation Across Amygdala Subnuclei in Rhesus Monkeys and Humans. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-10-30 Shawn Kamboj,Erin L Carlson,Bradley P Ander,Kari L Hanson,Karl D Murray,Julie L Fudge,Melissa D Bauman,Cynthia M Schumann,Andrew S Fox
OBJECTIVE Theories of amygdala function are central to our understanding of psychiatric and neurodevelopmental disorders. However, limited knowledge of the molecular and cellular composition of the amygdala impedes translational research aimed at developing new treatments and interventions. The aim of this study was to characterize and compare the composition of amygdala cells to help bridge the gap
-
Discrimination Exposure, Neural Reactivity to Stress, and Psychological Distress. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-10-30 Devon K Grey,Juliann B Purcell,Kristen N Buford,Mark A Schuster,Marc N Elliott,Susan Tortolero Emery,Sylvie Mrug,David C Knight
OBJECTIVE Discrimination exposure has a detrimental impact on mental health, increasing the risk of depression, anxiety, and posttraumatic stress. The impact discrimination exposure has on mental health is likely mediated by neural processes associated with emotion expression and regulation. However, the specific neural processes that mediate the relationship between discrimination exposure and mental
-
The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-10-09 Caesar G Imperio,Frances R Levin,Diana Martinez
Substance use disorder (SUD) is common in psychiatric patients and has a negative impact on health and well-being. However, SUD often goes untreated, and there is a need for psychiatrists, of all specialties, to address this pervasive clinical problem. In this review, the authors' goal is to provide a resource that describes treatments for SUD, using neuroscience as a framework. They discuss the effect
-
Association of Neuromelanin-Sensitive MRI Signal With Lifetime Substance Use in Young Women. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-10-09 Greg Perlman,Kenneth Wengler,Scott J Moeller,Roman Kotov,Daniel N Klein,Jodi J Weinstein,Guillermo Horga,Anissa Abi-Dargham
OBJECTIVE Midbrain dopamine function plays a key role in translational models of substance use disorders. Whether midbrain dopamine function is associated with substance use frequency and severity or reward function in 20-24 year-olds remains a critical gap in knowledge. The authors collected neuromelanin-sensitive magnetic resonance imaging (NM-MRI), a validated index of lifetime dopamine function
-
Identifying Genetically Inferred Effects Linking Posttraumatic Stress Disorder to Women's Health, Lipid Disorders, and Malaria Medications. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-10-09 Gita A Pathak,Frank R Wendt,Adam X Maihofer,,Kerry J Ressler,Murray B Stein,Karestan C Koenen,Caroline M Nievergelt,Renato Polimanti
-
Association of Cannabis Use Reduction With Improved Functional Outcomes: An Exploratory Aggregated Analysis From Seven Cannabis Use Disorder Treatment Trials to Extract Data-Driven Cannabis Reduction Metrics. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-10-09 Erin A McClure,Brian Neelon,Rachel L Tomko,Kevin M Gray,Aimee L McRae-Clark,Nathaniel L Baker
OBJECTIVE This exploratory analysis sought to determine whether decreases in cannabis use are associated with improvements in cannabis-related problems and functional outcomes, and if so, what percentage decrease is associated with improvement. METHODS Data were aggregated from seven cannabis use disorder treatment trials conducted in the United States (N=920; ages 13 years and older; mean age, 25
-
Aripiprazole Augmentation as a Treatment for Clozapine-Induced Weight Gain. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-10-01 Eric N Kramer,Vlad Velicu
-
Neural Circuitry and Therapeutic Targeting of Depressive Symptoms in Schizophrenia Spectrum Disorders. Am. J. Psychiatry (IF 15.1) Pub Date : 2024-10-01 Julia Gallucci,Ju-Chi Yu,Lindsay D Oliver,Hajer Nakua,Peter Zhukovsky,Erin W Dickie,Zafiris J Daskalakis,George Foussias,Daniel M Blumberger,Colin Hawco,Aristotle N Voineskos
OBJECTIVE Conceptual similarities between depressive and negative symptoms complicate biomarker and intervention development. This study employed a data-driven approach to delineate the neural circuitry underlying depressive and negative symptoms in schizophrenia spectrum disorders (SSDs). METHODS Data from three studies were analyzed (157 participants with SSDs) to assess brain-behavior relationships:
-
Clozapine's High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies-How Do We Get There? Am. J. Psychiatry (IF 15.1) Pub Date : 2024-10-01 K N Roy Chengappa,Robert O Cotes